The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 27, 2024

Filed:

Jul. 18, 2018
Applicants:

Kyowa Kirin Co., Ltd., Tokyo, JP;

Kyoto University, Kyoto, JP;

Inventors:

Masayuki Kai, Tokyo, JP;

Shinya Ogawa, Tokyo, JP;

Makoto Taketo, Kyoto, JP;

Kenji Kawada, Kyoto, JP;

Hideyo Hirai, Kyoto, JP;

Yoshiharu Sakai, Kyoto, JP;

Taira Maekawa, Kyoto, JP;

Assignees:

KYOWA KIRIN CO., LTD., Tokyo, JP;

KYOTO UNIVERSITY, Kyoto, JP;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/24 (2006.01); C07K 16/28 (2006.01); A61P 43/00 (2006.01); A61K 39/395 (2006.01); C12N 5/12 (2006.01); G01N 33/577 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2866 (2013.01); A61K 39/395 (2013.01); A61P 43/00 (2018.01); C12N 5/12 (2013.01); G01N 33/577 (2013.01);
Abstract

A monoclonal antibody is provided which binds to a human CC chemokine receptor 1 (CCR1) and inhibits activation of the human CCR1, or an antibody fragment thereof. The monoclonal antibody binds to an extracellular region of a human CCR1 and inhibits activation of the human CCR1 by a human CC chemokine ligand 15 (CCL15). An antibody fragment thereof, a hybridoma producing the antibody, a nucleic acid having a nucleotide sequence encoding the antibody or the antibody fragment, a transformant cell containing a vector containing the nucleic acid, a method for producing the antibody or the antibody fragment using the hybridoma or the transformant cell; a therapeutic agent and a diagnostic agent containing the antibody or the antibody fragment, and a method for treating and diagnosing a CCR1-related disease using the antibody or the antibody fragment are also provided.


Find Patent Forward Citations

Loading…